ClinicalTrials.gg

Program

Doxycycline

Also written as “Doxycycline Monohydrate”, “doxycycline monohydrate” and “doxycycline”.

Its studies are mostly in Rosacea · Acne Vulgaris · Fasting · Anthrax · Diabetic Foot, led by 10 companies.

Furthest: phase 4, since Jun 29, 200727 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Group80 open or runningphase 4since Jun 29, 2007Jul 19, 2002none ahead
Par Health50 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
AbbVie30 open or runningphase 4since Mar 7, 2008Jan 25, 2008none ahead
Viatris30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Sun Pharmaceutical Industries20 open or runningno phasesince Oct 17, 2008Oct 17, 2008none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
alacrity-biosciences-inc10 open or runningphase 2since Feb 22, 2007Feb 22, 2007none ahead
Dr. Reddy's Laboratories10 open or runningphase 2since Oct 19, 2017Oct 19, 2017none ahead
nanoshift-llc10 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
Pfizer10 open or runningphase 4since Jul 8, 2009Jul 8, 2009none ahead

Also a collaborator on its studies: Almirall and anapharm.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 19, 2002.

  1. Mar 7, 2008Phase 4 study in Acne VulgarisAbbVie · NCT00635609 · 93 enrolled · United States
  2. Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00649571, NCT00648180, NCT00647959
  3. Apr 1, 2008Par Health's first studies: 5 phase 1 studiesNew to Par HealthPar Health · NCT01380496, NCT01380483, NCT00653380 and 2 more
  4. Oct 1, 2008nanoshift-llc's first study: phase 2 study in Diabetic FootNew to nanoshift-llcnanoshift-llc · NCT00764361 · 15 enrolled · United States
  5. Oct 17, 2008Sun Pharmaceutical Industries's first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00775918, NCT00775177
  6. Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00829790, NCT00829764
  7. Apr 30, 2009Phase 4 study in RosaceaGalderma Group · NCT00892281 · 1,421 enrolled · United States
  8. Jul 8, 2009Pfizer's first study: phase 4 study in Bacterial InfectionsNew to PfizerPfizer · NCT00939562 · 24 enrolled · India
  9. Apr 28, 2010Phase 3 study in Chlamydia InfectionsAbbVie · NCT01113931 · 495 enrolled · United States
  10. Mar 2, 2011Phase 4 study in RosaceaGalderma Group · NCT01308619 · 170 enrolled · United States
  11. Aug 26, 2011Phase 4 study in RosaceaGalderma Group · NCT01426269 · 235 enrolled · United States
  12. Nov 16, 2011Phase 3 study in Acne VulgarisGalderma Group · NCT01474590 · 266 enrolled · Canada
  13. Mar 15, 2013Phase 4 study in RosaceaGalderma Group · NCT01872715 · 24 enrolled · United States
  14. Oct 19, 2017Dr. Reddy's Laboratories's first study: phase 2 study in RosaceaNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT03340961 · 205 enrolled · Germany

TargetBeta

“Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor”ChEMBL 37, by rule

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03340961Rosacea · Germany2CompletedDr. Reddy's LaboratoriesNov 7, 2018205
NCT01872715Rosacea · United States4CompletedGalderma GroupJun 201324
NCT01474590Acne Vulgaris · Canada3CompletedGalderma GroupJul 2013266
NCT01426269Rosacea · United States4CompletedGalderma GroupJun 2013235
NCT01308619Rosacea · United States4CompletedGalderma GroupAug 2012170
NCT01113931Chlamydia Infections · United States3CompletedAbbVieOct 2010495
NCT00939562Bacterial Infections · India4CompletedPfizerDec 200824
NCT00892281Rosacea · United States4CompletedGalderma GroupOct 20091,421
NCT00829790Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200630
NCT00829764Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200630
NCT00775918Healthy · United States–CompletedSun Pharmaceutical IndustriesJun 200532
NCT00775177Healthy · United States–CompletedSun Pharmaceutical IndustriesJun 200532
NCT00764361Diabetic Foot · United States2Completednanoshift-llcAug 201015
NCT01380496Lecithin Cholesterol Acyltransferase Deficiency · Canada1CompletedPar HealthNov 199924
NCT01380483Fasting · Canada1CompletedPar HealthApr 200040
NCT00653380Fasting · Canada1CompletedPar HealthOct 199924
NCT00652795Fasting · Canada1CompletedPar HealthSep 200436
NCT00652704Lecithin Cholesterol Acyltransferase Deficiency · Canada1CompletedPar HealthSep 199924
NCT00649571Healthy · United States1CompletedViatrisJul 200535
NCT00648180Healthy · United States1CompletedViatrisAug 200536
NCT00647959Healthy · United States1CompletedViatrisMar 200636
NCT00635609Acne Vulgaris · United States4CompletedAbbVieSep 200893
NCT00612573Acne Vulgaris · United States2CompletedAbbVieNov 2008257
NCT00495313Rosacea · United States4CompletedGalderma GroupDec 200791
NCT00439400Dry Eye Syndromes · United States2Completedalacrity-biosciences-inc160
NCT00126399Rosacea3CompletedGalderma Group528
NCT00041977Rosacea · United States3CompletedGalderma Group150

How it is read

Names in the registry

  • “Doxycycline Monohydrate”, 7 entries
  • “Doxycycline”, 5 entries
  • “doxycycline monohydrate”, 5 entries
  • “doxycycline”, 5 entries
  • “Doxycycline monohydrate 100mg tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.